SPOTLIGHT -
AI model predicts future DR progression in individual patients
Read More
AAO 2019: Single session devoted to diabetes
Raising awareness for diabetic eye disease
Sustained DRSS improvement with aflibercept
Several cyst characteristics linked to ischemia in DME
SWAP-TWO shows anatomic improvement after switch to aflibercept
Anti-VEGFs pose no additional risk of SAEs over other therapies
US, international physicians mostly in agreement over treatment practices
This year’s ASRS PAT survey show subtle regional differences
Global trends show similar patterns worldwide
The ASRS Global Trends Survey finds differences in some treatment preferences
Anti-VEGF expansion treats all DR stages
Read-through, gene therapies for LCA showing promise
Group of researchers aim to validate both approaches in proof-of-concept study
Programs provide patient assistance for AMD treatments
What’s in the wet AMD pipeline
ICYMI: State of AMD research in 2018
Pipeline for dry AMD holds promise
Arming AMD patients with knowledge
Talking about genetics and AMD
Celebrating retina research, future generation of EyeMDs
Fifteen fellows, residents showed just why research in retina is on the cutting edge
What newly diagnosed AMD patients need to know
Patient assistance programs can ease DME financial burden
Up-to-the-minute diabetic updates for your patients
Alternative dosing regimens to increase compliance in DME
Lessons learned from DRCR.net protocols
Diabetic eye disease: Best treatment options for your patients
November is Diabetic Eye Disease Awareness Month
DME: What it is and how to treat it
Commercial cell therapy clinics yield little evidence
Research finds limited publications and dearth of information about side effects
Imaging and Retinal Disorders
Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections
A study shows Alzheimer’s disease biomarkers in the vitreous
OCTA may be harbinger of anti-VEGF efficacy
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.